Why Did Enfusion Plunge 40.37%?

On April 17, 2025, Enfusion's stock experienced a significant drop of 40.37% in pre-market trading, raising concerns among investors and analysts alike.

Piper Sandler recently adjusted their price target for Enfusion, increasing it from $10.00 to $11.50 and maintaining a "neutral" rating. This adjustment reflects the firm's assessment of the company's current market position and future prospects.

Analysts have set an average price target of $12.25 for Enfusion, which is 13.27% higher than the current price. The consensus rating among analysts is "Buy," indicating a generally positive outlook on the stock's potential for growth.